# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biohaven (NYSE:BHVN) reported quarterly losses of $(3.50) per share which missed the analyst consensus estimate of $(1.77) by 9...
Morgan Stanley analyst Terence Flynn initiates coverage on Biohaven (NYSE:BHVN) with a Overweight rating and announces Price...
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.